Mitiglinide: A Novel Agent for the Treatment of Type 2 Diabetes Mellitus
| Autor: | Kurt A Wargo, Haley M Phillippe |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Clinical Trials as Topic
medicine.medical_specialty business.industry Insulin medicine.medical_treatment Type 2 Diabetes Mellitus Type 2 diabetes Isoindoles medicine.disease Meglitinide Mitiglinide Postprandial Endocrinology Diabetes Mellitus Type 2 Pharmacokinetics Diabetes mellitus Internal medicine medicine Humans Hypoglycemic Agents Pharmacology (medical) business medicine.drug |
| Zdroj: | Annals of Pharmacotherapy. 44:1615-1623 |
| ISSN: | 1542-6270 1060-0280 |
| DOI: | 10.1345/aph.1p136 |
| Popis: | Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of mitiglinide, a rapid-acting insulin secretion-stimulating agent to determine its potential role in therapy for the treatment of type 2 diabetes mellitus. Data Sources: A MEDLINE search (1966–May 2010) was conducted for English-language, human studies using the terms mitiglinide, KAD 1229, S 21403, and meglitinide analogs. Abstracts presented at the American Association and European Association for the Study of Diabetes annual meetings from 2005 to 2009 were also evaluated for relevant data. Study Selection and Data Extraction: Articles pertinent to the pharmacology, pharmacokinetics, efficacy, and safety of mitiglinide were reviewed. Data Synthesis: Mitiglinide has been shown through small clinical studies (N 1c, postprandial hyperglycemia, and oxidative stress and inflammatory markers associated with postprandial hyperglycemia. Mitiglinide exerts its hypoglycemic activity by closing adenosine triphosphate (ATP)–sensitive potassium channels in the β-islet cells of the pancreas. This agent has a rapid onset and short duration of action, mimicking a physiologic pattern of insulin release in nondiabetic people. Studies suggest a starting dose of 5 mg 3 times daily with meals and a maximum dose of 20 mg 3 times daily. Overall, mitiglinide is well tolerated, with the most common adverse effect being hypoglycemia. Conclusions: Mitiglinide is the third agent in the class of meglitinides that targets postprandial hyperglycemia. Because of a more intensive dosing regimen, potential cost, and lack of studies assessing the clinical impact of mitiglinide therapy on oxidative stress and inflammatory markers secondary to postprandial hyperglycemia, we cannot recommend this therapy over currently approved therapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|